The Gavi vaccine alliance, a global health partnership committed to increasing access to immunization in poor countries, has announced a decrease in pressure on cholera vaccine stocks. This development comes amid a surge in cholera outbreaks across Africa, exacerbated by climate change and other factors. Aurelia Nguyen, Gavi’s chief programme officer, provided an update on the current situation and the alliance’s efforts to boost vaccine production and supply.
Rising Demand for Cholera Vaccines
Cholera, a potentially deadly bacterial disease, has seen a resurgence in Africa, creating an urgent need for more vaccine doses. Historically, the demand for cholera vaccines was relatively low, with only two million doses supplied in 2013. However, the demand surged to 38 million doses by 2023 due to more frequent and widespread outbreaks, including in countries previously unaffected by the disease.
Strategic Adjustments in Vaccine Administration
In response to the escalating outbreaks, the World Health Organization (WHO) recommended administering a single dose of the cholera vaccine instead of the usual two-dose regimen. This strategy was implemented to extend the available vaccine supply and ensure more people are protected during outbreaks.
Increasing Vaccine Production Capacity
The pressure on cholera vaccine supplies, which was significant at the start of the year, is now easing. This improvement is largely due to increased production by EuBiologics, a South Korean biopharmaceutical company and the only current supplier of oral cholera vaccines. EuBiologics is set to boost its production by 30% in the coming year. Gavi’s long-term purchase agreements have played a crucial role in enabling this production increase.
To further diversify and enhance vaccine production, Gavi is collaborating with a second producer, the Indian company Bharat Biotech. Bharat is expected to supply additional doses starting in 2025. Additionally, future vaccine production in Africa is being planned as part of a broader initiative to strengthen local manufacturing capacities.
Climate Change and Emerging Health Risks
Climate change is a significant factor contributing to the increasing frequency and severity of cholera outbreaks. Gavi has integrated climate change considerations into its strategy for future vaccine needs. Global warming affects the spread of diseases, including those transmitted by mosquitoes and those related to population displacement due to drought or conflict.
Displaced populations, often in regions experiencing conflict, are at high risk for cholera and other infectious diseases. Gavi monitors these areas closely and maintains vaccine reserves for rapid deployment in response to outbreaks of cholera, yellow fever, meningitis, and measles.
Financial Preparedness and Rapid Response of Gavi Alliance
Gavi has allocated $500 million for rapid response to epidemics or pandemics, ensuring they can act swiftly when new health threats emerge. This financial readiness is crucial for managing outbreaks effectively and preventing widespread disease transmission.
Collaboration with Manufacturers
Gavi’s partnership with vaccine manufacturers is based on a model that balances affordability and sustainability. The alliance negotiates for reasonable prices without compromising on the quality of vaccines. This approach ensures that vaccines provided to children in poor countries are of the same high quality as those available in wealthier nations.
Gavi’s funding enables the vaccination of about 60% of the world’s children annually. The alliance emphasizes that it does not seek charity from manufacturers but aims to secure vaccines at the lowest possible prices to maximize the impact of its donor-funded resources.
The Gavi alliance’s efforts to increase cholera vaccine production and manage supply pressures are crucial in the fight against the disease’s resurgence in Africa. By working with multiple manufacturers and incorporating climate change into their strategic planning, Gavi is enhancing global health security. Their financial preparedness and commitment to quality ensure that vulnerable populations receive effective vaccines promptly. As cholera and other infectious diseases continue to pose significant threats, Gavi’s proactive measures and partnerships remain vital in protecting global health.
Join TISHHA.
